E-cadherin polymorphisms and haplotypes influence risk for prostate cancer

Prostate. 2006 Apr 1;66(5):546-56. doi: 10.1002/pros.20374.

Abstract

Background: The E-cadherin (CDH1) gene has been implicated in prostate cancer (PCA) risk, however, the exact mechanism is unknown. Several polymorphisms, such as the C/A variant -160 base pairs from the transcription start site, in the CDH1 gene promoter region have been associated with cancer risk, mainly in European descent populations.

Methods: We screened the entire coding region and 3.0 kilobases of the CDH1 promoter for polymorphisms in 48 African Americans using dHPLC. Twenty-one (21) polymorphisms were observed. Four polymorphisms, including -160C/A, were genotyped in a genetic association study using incident PCA cases (N = 427) and unaffected controls (N = 337) of similar age from three different ethnic groups consisting of African Americans, Jamaicans, and European Americans.

Results: We observed a significantly higher frequency of the -160A allele among European American PCA patients (27.5%) compared to the control group (19.7%) (P = 0.04). More importantly, among men of European ancestry under the age of 65 who possess the -160 A allele there was over three times increased risk for prostate cancer (P = 0.05). Also, the AACT haplotype bearing the -160A allele was significantly associated with PCA in European Americans (P = 0.04).

Conclusions: Our data indicate that CDH1 likely is a low-penetrant PCA susceptibility gene, however, population differences in linkage disequilibrium within the CDH1 gene region may influence the effect of susceptibility alleles such as -160A.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Aged
  • Black or African American / genetics
  • Cadherins / genetics*
  • Exons
  • Genetic Predisposition to Disease
  • Humans
  • Introns
  • Male
  • Middle Aged
  • Polymorphism, Genetic*
  • Promoter Regions, Genetic
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / epidemiology*
  • Prostatic Neoplasms / genetics*
  • Risk Factors
  • Sequence Deletion
  • United States

Substances

  • Cadherins
  • Prostate-Specific Antigen

Associated data

  • OMIM/124010
  • OMIM/192090
  • OMIM/601769
  • OMIM/605325
  • OMIM/607306